Table 3.
Univariate Cox Analyses of PFS and OS
| Variable | Category | PFS | OS | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age | ≥65 vs <65 | 0.702 (0.361–1.364) | 0.296 | 0.796 (0.412–1.541) | 0.499 |
| Gender | Female vs Male | 0.837 (0.396–1.771) | 0.642 | 0.663 (0.312–1.406) | 0.284 |
| BMI(kg/m2) | <18.5 or >23.9 vs.18.5–23.9 | 1.032 (0.530–2.011) | 0.926 | 1.076 (0.554–2.091) | 0.829 |
| Histology | Non-adenocarcinoma vs Adenocarcinoma | 1.096 (0.578–2.081) | 0.778 | 1.239 (0.655–2.344) | 0.509 |
| TNM stage | IV vs III | 1.333 (0.608–2.925) | 0.473 | 1.198 (0.549–2.617) | 0.650 |
| ECOG PS | ≥1 vs 0 | 1.049 (0.510–2.158) | 0.896 | 1.194 (0.575–2.478) | 0.634 |
| Smoking status | Former/Current vs Never | 1.315 (0.650–2.657) | 0.446 | 1.526 (0.757–3.078) | 0.238 |
| Actionable mutation | (-)/undetected vs (+) | 22.777 (0.041–12,505.518) | 0.331 | 22.628 (0.067–7697.921) | 0.294 |
| Metastasis | Yes vs No | 1.222 (0.557–2.681) | 0.617 | 1.036 (0.474–2.265) | 0.929 |
| Radiotherapy | Yes vs No | 2.087 (1.098–3.965) | 0.025 | 2.294 (1.204–4.368) | 0.012 |
| PD-L1 expression | ≥50% vs 0–50% | 0.226 (0.028–1.849) | 0.166 | 0.227 (0.028–1.867) | 0.168 |
| PD-L1 status | Positive vs Negative | 1.008 (0.126–8.082) | 0.994 | 0.933 (0.114–7.609) | 0.949 |
| Line of immunotherapy | ≥3 vs <3 | 1.299 (0.611–2.760) | 0.497 | 1.169 (0.552–2.475) | 0.683 |
| ICI substance | PD-1 vs PD-L1 | 0.663 (0.303–1.451) | 0.303 | 0.624 (0.286–1.365) | 0.238 |
| Mono-immunotherapy | Yes vs No | 1.933 (1.012–3.690) | 0.046 | 1.612 (0.841–3.087) | 0.150 |
| Immune adverse events | Yes vs No | 21.511 (0.012–37,969.388) | 0.421 | 21.115(0.003–133,441.458) | 0.495 |
| Leading STM at baseline | > the upper limit of normal vs < the upper limit of normal | 0.911 (0.341–2.430) | 0.852 | 0.981 (0.372–2.588) | 0.969 |
| Leading STM at 6 weeks | > the upper limit of normal vs < the upper limit of normal | 1.548 (0.611–3.923) | 0.357 | 1.523 (0.604 to 3.839) | 0.373 |
| Leading STM change | Decrease <20% vs Decrease ≥20% | 0.201 (0.081–0.502) | 0.001 | 0.275 (0.117–0.643) | 0.003 |
| Pretreatment NLR | ≥5 vs <5 | 0.524 (0.264–1.040) | 0.065 | 0.425 (0.213–0.848) | 0.015 |
| Posttreatment NLR | ≥5 vs <5 | 0.179 (0.091–0.35) | <0.0001 | 0.158 (0.080–0.314) | <0.0001 |
| NLR change | Decrease ≥20% vs Decrease <20% | 0.850 (0.448–1.614) | 0.620 | 0.892 (0.469–1.695) | 0.726 |
| Increase ≥20% vs Increase <20% | 1.720 (0.827–3.575) | 0.147 | 1.713 (0.827–3.551) | 0.148 | |
| Combination Score | 0 | ||||
| 1 | 3.150 (1.021–9.716) | 0.046 | 2.099 (0.731–6.028) | 0.168 | |
| 2 | 21.418 (6.975–65.763) | <0.0001 | 17.110 (5.943–49.260) | <0.0001 | |
Notes: Cox regression models were applied to find independent indicators associated with PFS and OS and estimate the hazard ratio (HR). Factors which were statistically significant in the univariate analysis were incorporated into the multivariate analysis. Figures are given as HR (95% CI). A P value of < 0.05 was regarded statistically significant.
Abbreviations: BMI, body mass index; TNM, tumor node metastasis; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune-checkpoint inhibitors; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; STM, serum tumor markers; NLR, neutrophil-to-lymphocyte ratio; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.